Experienced in Squamous Cell Lung Carcinoma

Dr. Amy H. Case

Pulmonary Medicine | Intensive Care Medicine
Piedmont Providers LLC
3820 Medical Park Dr, 
Austell, GA 
Accepting New Patients
Offers Telehealth
Experienced in Squamous Cell Lung Carcinoma
Piedmont Providers LLC
3820 Medical Park Dr, 
Austell, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Case is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Austell, Georgia. Dr. Case is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Gastrostomy. Dr. Case is currently accepting new patients.

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in GA
Hospital Affiliations
Piedmont Hospital, Inc
Wellstar Kennestone Regional Medical Center
Piedmont Fayette Hospital
Languages Spoken
English
Bulgarian
French
Mandarin
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

PIEDMONT PROVIDERS LLC
3820 Medical Park Dr, Austell, GA 30106
Other Locations
PIEDMONT PROVIDERS LLC
275 Collier Rd Nw, Suite 300, Atlanta, GA 30309
PIEDMONT PROVIDERS LLC
1984 Peachtree Rd Nw, Suite 300, Atlanta, GA 30309

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
Pulmonary Fibrosis Foundation Patient Registry
Pulmonary Fibrosis Foundation Patient Registry
Enrollment Status: Completed
Publish Date: July 07, 2023
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

18 Total Publications

Reply to Borrás-Blasco et al.: How Adherence Shapes Persistence in IPF Treatment: A Call for Real-World Insight.
Reply to Borrás-Blasco et al.: How Adherence Shapes Persistence in IPF Treatment: A Call for Real-World Insight.
Journal: Annals of the American Thoracic Society
Published: September 12, 2025
Similar Doctors
Advanced in Squamous Cell Lung Carcinoma
Dr. Lawrence D. Kaplan
Intensive Care Medicine | Pulmonary Medicine
Advanced in Squamous Cell Lung Carcinoma
Dr. Lawrence D. Kaplan
Intensive Care Medicine | Pulmonary Medicine

Gwinnett Pulmonary Group - Athena

3855 Pleasant Hill Rd., Suite 180, 
Duluth, GA 
 (27.0 miles away)
770-995-0630
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Kaplan is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Duluth, Georgia. Dr. Kaplan is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Hospital-Acquired Pneumonia, Atypical Pneumonia, and Advanced Bronchoscopy. Dr. Kaplan is currently accepting new patients.

Advanced in Squamous Cell Lung Carcinoma
Dr. Thomas P. Demarini
Pulmonary Medicine | Intensive Care Medicine
Advanced in Squamous Cell Lung Carcinoma
Dr. Thomas P. Demarini
Pulmonary Medicine | Intensive Care Medicine
2665 N Decatur Rd, Ste 430, 
Decatur, GA 
 (19.0 miles away)
404-294-4018
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Thomas Demarini is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Decatur, Georgia. Dr. Demarini is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are EGFR Positive Lung Cancer, Squamous Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Demarini is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Christopher S. Parks
Pulmonary Medicine
Distinguished in Squamous Cell Lung Carcinoma
Dr. Christopher S. Parks
Pulmonary Medicine

City Of Hope Medical Group Of Georgia LLC

600 Celebrate Life Pkwy, 
Newnan, GA 
 (34.1 miles away)
770-400-6080
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Christopher Parks is a Pulmonary Medicine provider in Newnan, Georgia. Dr. Parks is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Endoscopy. Dr. Parks is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Case's expertise for a condition
ConditionClose
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile